Angela Kalia
Family Medicine · Washington, PANPI 1952922882
Payments from drug & device makers
Across 75 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$246
- AbbVie$169
- Johnson & Johnson$149
- Pfizer$124
- Lilly USA, LLC$104
- GSK$92
- plus $587 from 14 others
What the payments were for
- Food & beverage$1,471100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $246 |
| AbbVie | 10 | $169 |
| Johnson & Johnson(2 entities) | 3 | $149 |
| Pfizer | 6 | $124 |
| Lilly USA, LLC | 5 | $104 |
| GSK | 5 | $92 |
| Exact Sciences | 4 | $88 |
| Amgen | 6 | $84 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
| Dexcom, Inc. | 4 | $66 |
| Inspire Medical Systems, Inc. | 1 | $42 |
| Novartis | 2 | $41 |
| Vertex | 1 | $33 |
| Merck | 2 | $29 |
| AstraZeneca | 2 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$110
How this compares
$1,471 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $37,415 |
| JardianceEmpagliflozin | 39 | $34,768 |
| EliquisApixaban | 18 | $13,699 |
| MounjaroTirzepatide | 12 | $12,245 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,218 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $930 |
| Gabapentin | 63 | $741 |
| Atorvastatin Calcium | 83 | $575 |
| Lisinopril | 74 | $452 |
| Amlodipine Besylate | 56 | $338 |
| Levothyroxine Sodium | 37 | $321 |
| Fluticasone Propionate | 27 | $244 |
| Simvastatin | 31 | $242 |
| Pantoprazole Sodium | 34 | $229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $246 | $37,41539 claims |
| Boehringer IngelheimJardiance | $22 | $34,76839 claims |
| PfizerEliquis | $124 | $13,69918 claims |
| Lilly USA, LLCMounjaro | $104 | $12,24512 claims |
| GSKBreo Ellipta | $92 | $6,41114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Washington
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.